RPG Life Sciences (RPGLIFE) Q2 24/25 earnings summary

Executive summary

• Achieved strong double-digit growth in H1 FY25, with all business segments contributing and continued margin expansion year-over-year.

• Transformation agenda focused on growth, digitalization, and operational excellence is driving sustained profitability and business scale-up.

• Unaudited financial results for the quarter and half year ended September 30, 2024, were approved by the Board on November 7, 2024.

• The independent auditor's review found no material misstatements in the financial statements.

Financial highlights

• Revenue from operations rose 12% to ₹337.6 Cr in H1 FY25, with Q2 FY25 revenue at ₹17,221 lakhs, up from ₹15,358 lakhs in Q2 FY24.

• EBITDA increased 22% to ₹89.3 Cr, with margin expanding to 27.8% in Q2 FY25.

• PAT grew 21% to ₹58.3 Cr, with margin at 17.3%.

• Earnings per share (adjusted) for H1 FY25 was ₹35.2, up from ₹29.0 in H1 FY24.

• Net cash inflow from operating activities for H1 FY25 was ₹4,633 lakhs, up from ₹3,424 lakhs in H1 FY24.

Outlook and guidance

• Focus on expanding international formulations and API segments, supported by plant modernization and capacity expansion.

• Strategic framework includes seven pillars: state-of-the-art plants, targeted R&D, innovation, digitalization, inorganic growth (M&A), MedTech adjacency, and talent development.

• Non-current assets of ₹1,201 lakhs reclassified as held for sale, pending completion of a land assignment transaction.